Sanofi Looks To Enter Cancer Vaccine Field With TroVax Acquisition
A collaboration between Sanofi-Aventis and Oxford BioMedica in the area of therapeutic cancer vaccines could extend beyond the development of TroVax to second-generation therapeutic vaccines combining technology from both companies, Sanofi Senior VP-Head of Oncology Allain Herrera said
You may also be interested in...
A pharmacovigilence study involving roughly 3,000 patients would be conducted by Dendreon to monitor safety events associated with Provenge, if FDA approves the therapeutic cancer vaccine
Although not convinced that existing data fully prove the efficacy of Dendreon's Provenge, a majority of FDA's Cellular, Tissue and Gene Therapies Advisory Committee agreed during a March 29 meeting that there is "substantial evidence" the biologic is effective and should be approved
Antigenics is seeing salvation for its Oncophage cancer vaccine based on signs of a clinically significant improvement in a subgroup of patients with a better prognosis in its Phase III renal cell carcinoma trial